

HEMATOLOGICAL MALIGNANCIES RESEARCH HORIZONS

March 1st 2022 – Tel Aviv University

08:00 – 08:45 **Registration and Reception**

09:00 – 09:30 **Greetings and Ceremony**

Prof. Ariel Porat - President of Tel Aviv University

Prof. Ehud Grossman - Dean Sackler Faculty of Medicine

Prof. Dan Peer - Vice President for Research & Development

Prof. Shai Izraeli – Chair, the Varda and Boaz Dotan Center for Hemato-Oncology Research

09:30 – 10:15 **Session I: Plenary**

Chair: Shai Izraeli

09:30 – 10:15 Translational Research in Blood Cancers - the Vision of City of Hope
Steven T. Rosen, City of Hope National Medical Center

10:15 – 12:00 **Session II: Myeloid Malignancies**

Chairs: Yishai Ofran, Martin Ellis

10:15 – 10:35 Mechanisms of Competition Between Healthy and Malignant Hematopoiesis
Cristina Lo Celso, Imperial College London

10:35 – 10:50 Regulation of DNA Damage Response in Normal and Leukemic Blood Stem Cell
Michael Milyavsky, Sackler Faculty of Medicine

10:50 – 11:05 From a Fortuitous Discovery to Treatment of AML
Shai Izraeli, Schneider Children's Medical Center Israel

11:05 – 11:20 Epitranscriptomics - From Basic Research to Leukemia Therapy



- Gidi Rechavi**, Sheba Medical Center, Tel Hashomer
- 11:20 – 11:40** RNA Methylation and the Regulators of Cellular Fate.
- Michael G. Kharas**, Memorial Sloan Kettering Cancer Center
- 11:40 – 12:00** **Discussion**
- 12:00 – 12:20** **Coffee break**
- 12:20 – 13:40** **Session III: Immunotherapies and Targeted Therapies**
Chairs: Drorit Neumann, Irit Avivi
- 12:20 – 12:35** Therapeutic Gene Manipulation in Multiple Myeloma.
Dan Peer, Faculty of Life Sciences, Tel Aviv University
- 12:35 – 12:50** CAR-T cells and CNS Leukemia
Elad Jacoby, Sheba Medical Center, Tel Hashomer
- 12:50 – 13:05** A Unique Engineered T Cell Enables Antibody-Mediated Cytotoxicity to Overcome the Limitations of CAR T Cell Therapy
Yaron Carmi, Sackler Faculty of Medicine
- 13:05 – 13:20** Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated with CD19 - Chimeric Antigen Receptor T-Cell Therapy
Roni Shouval, Memorial Sloan Kettering Cancer Center
- 13:20 – 13:40** **Discussion**
- 13:40 – 14:30** **Lunch break**
- 14:30 – 15:00** **Session IV: Plenary**
Chair: Abraham Avigdor
- 14:30 – 15:00** Targeting the Microenvironment in Lymphoid Malignancies



John Gribben, Saint Bartholomew's Hospital, Queen Mary's School of
Medicine, University of London

15:00 – 16:25 **Session V: Lymphoid Malignancies**

Chairs: Pia Raanani, Moshe Gat

15:00 – 15:20 B-Precursor ALL in Children: Prevention is Better than Cure

Arndt Borkhardt, University Hospital, Heinrich-Heine-University,
Düsseldorf

15:20 – 15:35 Leveraging on Single Cell RNA-Sequencing and AI Technologies Towards
Personalized Therapy in Myeloma.

Yael Cohen, Tel Aviv Sourasky Medical Center

15:35 – 15:50 Reprogramming of Bone Marrow Mesenchymal Stem Cells:
Next Frontier in Myeloma Progression Markers

Liat Drucker, Meir Medical Center

15:50 – 16:05 B-Cell Receptor Spatial Organization, Early Signaling and
its Targeting in CLL

Yair Herishanu, Tel Aviv Sourasky Medical Center

16:05 – 16:25 **Discussion and Concluding Remarks**

